Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

June 30, 2017

Study Completion Date

December 30, 2017

Conditions
Brain Tumors
Interventions
DRUG

temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid

13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.

Trial Locations (17)

10016

NYU Hassenfeld Center, New York

11040

Steven and Alexandra Cohen Children's Medical Center of New York- North Shore LIJ, New Hyde Park

14263

Roswell Park Cancer Institute, Buffalo

19104

Children's Hospital of Philadelphia, Philadelphia

23284

Virginia Commonwealth Univ., Richmond

29425

Medical Univ. of South Carolina, Charleston

30322

Emory University, Atlanta

37240

Vanderbilt Univ., Nashville

43205

Nationwide Children's Hospital, Columbus

46202

Riley Hospital for Children, Indianapolis

55404

Children's Hospital and Clinics of Minnesota, Minneapolis

60614

Children's Memorial Hospital, Chicago

75235

Children's Medical Center of Dallas, Dallas

77030

MD Anderson Cancer Center (MDACC), Houston

85016

Phoenix Children's Hospital, Phoenix

96766

Hawaii Pacific Health, Lihue

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

Children's Hospitals and Clinics of Minnesota

OTHER

collaborator

Schneider Children's Hospital

OTHER

lead

NYU Langone Health

OTHER

NCT00528437 - Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors | Biotech Hunter | Biotech Hunter